Claret Medical said today that the 1st patient has been treated in a U.S. pivotal trial of its Sentinel cerebral protection system, which is designed to guard against stroke during transcatheter aortic valve implantation.
Replacement Heart Valves
Wall Street loves Edwards Lifesciences again
Edwards Lifesciences (NYSE:EW) is back in Wall Street’s good graces, with shares of the Irvine, Calif.-based heart valve maker approaching all time highs after nearly 2 years of down performance.
TAVI: Direct Flow Medical wins CE Mark for enhanced heart valve delivery device
Analyst: Edwards Lifesciences’ Sapien 3 poised to lead TAVI market | MassDevice.com On Call
MASSDEVICE ON CALL — Edwards Lifesciences (NYSE:EW) is poised to take the lead in the transcatheter aortic valve market with its Sapient 3 replacement heart valve, according to Leerink Partners analyst Danielle Antalffy.
Mitralign reports 1st-in-human tricuspid valve repair
Replace aortic valve in a timely fashion: researchers
NEW YORK (Reuters Health) – Patients with severe symptomatic aortic stenosis who need aortic valve replacement should have the surgery as soon as possible, new research suggests.
"Our research highlights the importance of treating aortic stenosis in a timely fashion. Delays lead to unnecessary risk and patients should ideally have an aortic valve replacement within a month of diagnosis," Dr. Chris Malaisrie of Northwestern University, Feinberg School of Medicine, in Chicago, Illinois, told Reuters Health by email.
TAVI: Boston Scientific launches U.S. Lotus valve trial
DeviceTalks podcast: Edwards Lifesciences CEO Michael Mussallem
Abiomed touts survival rates for its Impella right-side heart pump | TCT 2014 Roundup
Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.
Researchers reported an overall 73% 30-day survival rate in the small study of patients with right ventricular heart failure, according to data Abiomed released during the Transcatheter Cardiovascular Therapeutics conference in Washington D.C.